Watch VOR. Know when insiders buy.
One email the day a filing lands. Free.
VOR
Vor Biopharma Inc.
18.69
+0.63 +3.49%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · shorts 40
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1BP/E 0.1DIV YIELD —FCF YIELD -12.73%REV TTM —NET INCOME $627.8MNET CASH —52W 6.86 – 37.46SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$47.9M | −$62.8M | — | -1.16 | −$25.4M | $120K | −$25.5M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$35.2M | −$219.6M | — | -5.11 | −$38.2M | $48K | −$38.3M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$36M | $1.7B | — | 307.61 | −$22.8M | $314K | −$23.1M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$28.1M | −$812.7M | — | -121.63 | −$53.7M | $244K | −$53.9M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$274.3M | −$1.6B | — | -251.24 | −$35.2M | $152K | −$35.3M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$33.3M | −$32.5M | — | -5.21 | −$31.1M | $231K | −$31.3M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$31.3M | −$30.7M | — | -8.78 | −$24.1M | $72K | −$24.1M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$28.5M | −$27.6M | — | -8.05 | −$23.3M | $34K | −$23.3M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$29M | −$27.8M | — | -0.41 | −$21.8M | $9K | −$21.9M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$32.3M | −$30.8M | — | -0.45 | −$30.5M | $114K | −$30.6M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$28.1M | −$26.3M | — | -0.38 | −$24M | $111K | −$24.1M | Mar 20 |
| Q3 2023 · Sep 30 | — | — | — | −$35.3M | −$33.2M | — | -0.49 | −$27.9M | $465K | −$28.4M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$371.6M | −$696M | — | -70.50 | −$142.7M | $941K | −$143.7M | — | $0 |
| FY2024 · to Dec 31 | — | — | −$121.2M | −$116.9M | — | -34.03 | −$99.7M | $229K | −$99.9M | — | $0 |
| FY2023 · to Dec 31 | — | — | −$126M | −$117.9M | — | -1.75 | −$100.3M | $1.1M | −$101.4M | — | $0 |
| FY2022 · to Dec 31 | — | — | −$93.4M | −$92.1M | — | -2.33 | −$85.1M | $8.5M | −$93.6M | — | $0 |
| FY2021 · to Dec 31 | — | — | −$69M | −$68.9M | — | -2.10 | −$69.1M | $3.9M | −$73M | — | $0 |
| FY2020 · to Dec 31 | — | — | −$43.4M | −$43.3M | — | -230.57 | −$36.3M | $4.2M | −$40.5M | — | $0 |
Every number comes from Vor Biopharma Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.